Citicoline

background

Citicoline was first used to treat stroke. Citicoline may help treat diseases of the nerves and brain. Citicoline may help prevent the release of harmful chemicals in the body after decreased blood flow to the brain.
Citicoline has been studied as a treatment for disorders associated with aging, including memory loss, glaucoma (increased eye pressure), and problems with nerve function.
Citicoline is used in Europe and Japan for stroke, head injury, and other nerve diseases.

Related Terms

CDP, Cebrolux®, Cebroton, Cognizin®, cytidine diphosphate choline, cytidine-5'-diphosphocholine, cytidinediphosphocholine, diphosphocholine, Neuroton®, somazina.
Note: The terms citicoline, citicholine, and CDP-choline are used interchangeably throughout the literature. "Citicoline" will be used throughout this monograph.

evidence table

These uses have been tested in humans or animals. Safety and effectiveness have not always been proven. Some of these conditions are potentially serious, and should be evaluated by a qualified healthcare provider.
 
Stroke (Grade: B)
Citicoline was first used by Ferrer International for the treatment of stroke. It is used in Europe and Japan for stroke. Research suggests that citicoline may protect the brain and nerves. Additional research is needed in this area.
Aging (brain) (Grade: C)
Research suggests that citicoline may help treat people with mild-to-moderate brain aging. Additional research is needed in this area.
Alzheimer's disease (Grade: C)
Research suggests that citicoline may help people with Alzheimer's disease. It may improve thinking and increase blood flow to the brain. Additional research is needed in this area.
Bipolar disorder (added to conventional treatment) (Grade: C)
Research suggests that citicoline lack an effect on depression symptoms. Additional research is needed in this area.
Brain damage (Grade: C)
Research suggests that citicoline may help people with brain damage. Additional research is needed in this area.
Cerebral insufficiency (decreased blood flow to the brain) (Grade: C)
Research suggests that use of citicoline may help people with disorders of the blood vessels in the brain. Additional research is needed in this area.
Cocaine dependence (Grade: C)
Research suggests a lack of effect of citicoline on cocaine dependence. Additional research is needed in this area.
Delirium (Grade: C)
Research suggests citicoline has a small effect on delirium. Additional research is needed in this area.
Dementia (Grade: C)
Research suggests citicoline may benefit people with dementia. Additional research is needed in this area.
Depression (Grade: C)
Research suggests citicoline may help people with depression. Additional research is needed in this area.
Eye disorders (Grade: C)
Research suggests that citicoline may help treat amblyopia ("lazy eye"). Additional research is needed in this area.
Glaucoma (increased eye pressure) (Grade: C)
Research suggests that citicoline may help treat glaucoma. Additional research is needed in this area.
Hemorrhage (bleeding) (Grade: C)
Research suggests citicoline may help treat people with bleeding in the brain. Additional research is needed in this area.
Memory loss (Grade: C)
Research suggests that citicoline may help improve memory in the elderly and in people with brain injury due to trauma. Additional research is needed in this area.
Muscle strength (Grade: C)
Research suggests that citicoline may increase muscle strength in people with cerebral hemorrhage (bleeding in the brain) that is not caused by trauma. Additional research is needed in this area.
Neuropathy (Grade: C)
Research suggests that use of citicoline in people with nonarteritic ischemic optic neuropathy (NION), a type of nerve damage in the eye, improved vision. Additional research is needed in this area.
Parkinson's disease (Grade: C)
Research shows mixed results of citicoline in people with Parkinson's disease. It has been given with the normal levodopa treatment. Additional research is needed in this area.
Tardive dyskinesia (Grade: C)
There is a lack of well-designed research to support the use of citicoline for the movement disorder tardive dyskinesia. Additional research is needed in this area.